Product NDC: | 0093-5506 |
Proprietary Name: | Olanzapine and Fluoxetine |
Non Proprietary Name: | Olanzapine and Fluoxetine |
Active Ingredient(s): | 25; 12 mg/1; mg/1 & nbsp; Olanzapine and Fluoxetine |
Administration Route(s): | ORAL |
Dosage Form(s): | CAPSULE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0093-5506 |
Labeler Name: | Teva Pharmaceuticals USA Inc |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA077528 |
Marketing Category: | ANDA |
Start Marketing Date: | 20120619 |
Package NDC: | 0093-5506-56 |
Package Description: | 30 CAPSULE in 1 BOTTLE (0093-5506-56) |
NDC Code | 0093-5506-56 |
Proprietary Name | Olanzapine and Fluoxetine |
Package Description | 30 CAPSULE in 1 BOTTLE (0093-5506-56) |
Product NDC | 0093-5506 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Olanzapine and Fluoxetine |
Dosage Form Name | CAPSULE |
Route Name | ORAL |
Start Marketing Date | 20120619 |
Marketing Category Name | ANDA |
Labeler Name | Teva Pharmaceuticals USA Inc |
Substance Name | FLUOXETINE HYDROCHLORIDE; OLANZAPINE |
Strength Number | 25; 12 |
Strength Unit | mg/1; mg/1 |
Pharmaceutical Classes | Atypical Antipsychotic [EPC],Serotonin Reuptake Inhibitor [EPC],Serotonin Uptake Inhibitors [MoA] |